Is the Options Market Predicting a Spike in Celldex (CLDX) Stock?Zacks Investment Research • 01/10/22
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo NodularisGlobeNewsWire • 12/08/21
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/10/21
Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/21
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/28/21
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021GlobeNewsWire • 09/29/21
Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-MakersSeeking Alpha • 09/23/21
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th CongressGlobeNewsWire • 09/23/21
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/05/21
Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/29/21
Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease CandidateBenzinga • 07/14/21
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common StockGlobeNewsWire • 07/14/21
Celldex's Latest Data For Chronic Inducible Urticaria Drug Is Only The BeginningSeeking Alpha • 07/13/21
Celldex's stock jumps on positive data from early-stage, open-label clinical trial for hives treatmentsMarket Watch • 07/12/21